Home › Companies › Catalyst Pharmaceuticals, Inc. › 2024-2025

Catalyst Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Catalyst Pharmaceuticals, Inc.’s Form 8-K, filed 2025-05-23 (Item 5.07 on EDGAR). Page generated 04 October 2026.

14Reported items
390Asset managers
4,140Fund votes
2025-05-20Meeting date

Proxy season: 2023-2024 2024-2025

Explore Catalyst Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Catalyst Pharmaceuticals, Inc.

These tallies are Catalyst Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Catalyst Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2025-05-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Richard J. Daly	87,947,782	1,372,592	102,057	--	11,793,160	Majority: yes
Elect Director: Patrick J. McEnany	82,282,446	7,039,324	100,661	--	11,793,160	Majority: yes
Elect Director: Donald A. Denkhaus	87,993,958	1,329,212	99,261	--	11,793,160	Majority: yes
Elect Director: Molly Harper	88,259,042	1,040,685	122,704	--	11,793,160	Majority: yes
Elect Director: Tamar Thompson	85,761,231	3,562,397	98,803	--	11,793,160	Majority: yes
Elect Director: David S. Tierney	84,527,122	4,751,403	143,906	--	11,793,160	Majority: yes
Proposal 2: Approval of an amendment to our 2018 Stock Incentive Plan:	85,350,862	3,975,602	95,967	--	11,793,160	Majority: yes
Proposal 3: Approval, on an advisory basis, of the 2024 compensation of our named executive officers:	82,734,939	6,484,020	203,472	--	11,793,160	Majority: yes
Proposal 4: Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:	99,942,142	1,211,668	61,781	--	--	Majority: yes

Source: Catalyst Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-05-23 — read the filing on EDGAR.

How asset managers voted at the Catalyst Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 390 asset managers that disclosed a Catalyst Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Catalyst Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the 2024 compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 82,734,939AGAINST: 6,484,020

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the 2024 compensation of our named executive officers:”): 82,734,939 for, 6,484,020 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 68% for, 5% against (73% of the company cast a for/against vote).

The 382 asset managers below cast 90% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 90%10%

FOR: 89.9%AGAINST: 9.9%ABSTAIN: 0.1%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the 2024 compensation of our named executive officers.” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	17,524,477	27,382	For
Vanguard	8,551,148	4,685	For
State Street	8,081,479	38,653	For
Fidelity	3,229,084	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,755,989	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	2,598,901	0	For
Charles Schwab	2,527,484	0	For
Fundsmith LLP	0	2,151,274	Against
Invesco	0	1,895,518	Against
Dimensional	1,864,710	0	For
T. Rowe Price	1,763,978	0	For
Renaissance	1,418,682	0	For
Northern Trust	1,411,368	5,449	For
Nuveen	1,248,350	0	For
Royce	1,238,139	0	For
TIAA	1,236,505	0	For
Boston Partners	1,176,609	0	For
Goldman Sachs	1,157,028	0	For
Aberdeen	0	1,051,523	Against
American Century	0	1,017,605	Against
KENNEDY CAPITAL MANAGEMENT LLC	950,798	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	942,298	0	For
Pacer Funds Trust	854,367	0	For
MELLON INVESTMENTS Corp	734,054	0	For
JUPITER ASSET MANAGEMENT LTD	661,020	0	For

Showing the 25 largest of 382 asset managers. See all 382 in the interactive database.

2. To approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by 5 million shares.

COMPENSATIONMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 85,350,862AGAINST: 3,975,602

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Approval of an amendment to our 2018 Stock Incentive Plan:”): 85,350,862 for, 3,975,602 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 70% for, 3% against (73% of the company cast a for/against vote).

The 121 asset managers below cast 98% of the shares they voted on this item FOR (42,519,387 for, 687,524 against).

FOR 98%

FOR: 42,519,387 (98.4%)AGAINST: 687,524 (1.6%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by 5 mi” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,813,960	0	For
Vanguard	8,245,656	7	For
State Street	2,953,628	148	For
Fidelity	2,911,966	0	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	0	491,036	Against
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	329,643	0	For
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 121 asset managers. See all 121 in the interactive database.

3. To elect David S. Tierney, M.D. as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 84,527,122AGAINST: 4,751,403

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David S. Tierney”): 84,527,122 for, 4,751,403 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 69% for, 4% against (73% of the company cast a for/against vote).

The 114 asset managers below cast 99% of the shares they voted on this item FOR (42,625,145 for, 514,923 against).

FOR 99%

FOR: 42,625,145 (98.8%)AGAINST: 514,923 (1.2%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To elect David S. Tierney, M.D. as a member of the Board of Directors until the 2026 Annual Meeting of Stockho” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,813,960	0	For
Vanguard	8,240,979	4,684	For
State Street	2,953,628	148	For
Fidelity	2,911,966	0	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	491,036	0	For
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	0	329,643	Against
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

4. To elect Donald A. Denkhaus as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 87,993,958AGAINST: 1,329,212

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Donald A. Denkhaus”): 87,993,958 for, 1,329,212 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 72% for, 1% against (73% of the company cast a for/against vote).

The 114 asset managers below cast 99.6% of the shares they voted on this item FOR (42,993,967 for, 146,100 against).

FOR 99.6%

FOR: 42,993,967 (99.6%)AGAINST: 146,100 (0.3%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To elect Donald A. Denkhaus as a member of the Board of Directors until the 2026 Annual Meeting of Stockholder” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,813,960	0	For
Vanguard	8,240,985	4,677	For
State Street	2,953,776	0	For
Fidelity	2,911,966	0	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	491,036	0	For
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	329,643	0	For
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

5. To elect Molly Harper as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until her earlier death, disability or resignation:

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 88,259,042AGAINST: 1,040,685

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Molly Harper”): 88,259,042 for, 1,040,685 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 72% for, 0.9% against (73% of the company cast a for/against vote).

The 114 asset managers below cast 99.9% of the shares they voted on this item FOR (43,123,369 for, 16,699 against).

FOR 99.9%

FOR: 43,123,369 (99.9%)AGAINST: 16,699 (0.0%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To elect Molly Harper as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or ” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,813,960	0	For
Vanguard	8,240,986	4,677	For
State Street	2,953,776	0	For
Fidelity	2,911,966	0	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	491,036	0	For
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	329,643	0	For
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

6. To elect Patrick J. McEnany as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 82,282,446AGAINST: 7,039,324

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Patrick J. McEnany”): 82,282,446 for, 7,039,324 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 67% for, 6% against (73% of the company cast a for/against vote).

The 114 asset managers below cast 93% of the shares they voted on this item FOR (40,132,490 for, 3,007,578 against).

FOR 93%

FOR: 40,132,490 (93.0%)AGAINST: 3,007,578 (7.0%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To elect Patrick J. McEnany as a member of the Board of Directors until the 2026 Annual Meeting of Stockholder” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,813,960	0	For
Vanguard	8,240,984	4,678	For
State Street	63,822	2,889,954	Against
Fidelity	2,911,966	0	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	491,036	0	For
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	329,643	0	For
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

7. To elect Richard J. Daly as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 87,947,782AGAINST: 1,372,592

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard J. Daly”): 87,947,782 for, 1,372,592 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 72% for, 1% against (73% of the company cast a for/against vote).

The 114 asset managers below cast 99.9% of the shares they voted on this item FOR (43,129,720 for, 10,348 against).

FOR 99.9%

FOR: 43,129,720 (99.9%)AGAINST: 10,348 (0.0%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To elect Richard J. Daly as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, ” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,813,960	0	For
Vanguard	8,245,660	3	For
State Street	2,953,628	148	For
Fidelity	2,911,966	0	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	491,036	0	For
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	329,643	0	For
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

8. To elect Tamar Thompson as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until her earlier death, disability or resignation:

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 85,761,231AGAINST: 3,562,397

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Tamar Thompson”): 85,761,231 for, 3,562,397 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 70% for, 3% against (73% of the company cast a for/against vote).

The 114 asset managers below cast 98% of the shares they voted on this item FOR (42,444,993 for, 695,075 against).

FOR 98%

FOR: 42,444,993 (98.3%)AGAINST: 695,075 (1.6%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To elect Tamar Thompson as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, o” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,231,829	582,131	For
Vanguard	8,240,980	4,683	For
State Street	2,953,776	0	For
Fidelity	2,815,752	96,214	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	491,036	0	For
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	329,643	0	For
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

9. To ratify the selection of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 99,942,142AGAINST: 1,211,668

Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:”): 99,942,142 for, 1,211,668 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,959,172 outstanding shares: 82% for, 1.0% against (83% of the company cast a for/against vote).

The 114 asset managers below cast 99.7% of the shares they voted on this item FOR (43,012,831 for, 127,237 against).

FOR 99.6%

FOR: 43,012,831 (99.6%)AGAINST: 127,237 (0.3%)ABSTAIN: 24,148 (0.1%)

Largest asset managers voting on “To ratify the selection of Grant Thornton LLP as our independent registered public accounting firm for the fis” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	12,813,960	0	For
Vanguard	8,245,661	2	For
State Street	2,953,628	148	For
Fidelity	2,911,966	0	For
Dimensional	1,600,257	0	For
TIAA	1,236,505	0	For
Charles Schwab	1,202,971	0	For
Royce	1,141,617	0	For
Pacer Funds Trust	854,367	0	For
Invesco	829,473	0	For
T. Rowe Price	719,930	0	For
Waddell & Reed	634,570	0	For
American Century	491,036	0	For
OBERWEIS FUNDS	467,100	0	For
Goldman Sachs	391,456	0	For
Aberdeen	329,643	0	For
Equitable	294,963	0	For
World Funds Trust	266,124	0	For
Northern Trust	263,318	0	For
Janus Detroit Street Trust	257,889	0	For
SEI	256,097	0	For
Prudential/PGIM	243,921	0	For
First Trust	236,665	0	For
Columbia Threadneedle	236,483	0	For
Jackson National	224,018	0	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

10. To transact such other business as may properly come before the meeting.

CORPORATE GOVERNANCE

1% fund support · no official result

AGAINST 99%

The 110 asset managers below cast 1% of the shares they voted on this item FOR (456,674 for, 42,476,319 against).

FOR: 456,674 (1.1%)AGAINST: 42,476,319 (98.8%)ABSTAIN: 57,208 (0.1%)

Largest asset managers voting on “To transact such other business as may properly come before the meeting.” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Vote
BlackRock	0	12,813,960	0	Against
Vanguard	11,898	8,233,764	1	Against
State Street	5,108	2,948,668	0	Against
Fidelity	0	2,911,966	0	Against
Dimensional	0	1,600,257	0	Against
TIAA	0	1,236,505	0	Against
Charles Schwab	0	1,202,971	0	Against
Royce	0	1,141,617	0	Against
Pacer Funds Trust	0	854,367	0	Against
Invesco	0	829,473	0	Against
T. Rowe Price	0	719,930	0	Against
Waddell & Reed	0	634,570	0	Against
American Century	0	491,036	0	Against
OBERWEIS FUNDS	0	467,100	0	Against
Goldman Sachs	0	391,456	0	Against
Aberdeen	0	329,643	0	Against
Equitable	0	294,963	0	Against
World Funds Trust	0	266,124	0	Against
Northern Trust	0	263,318	0	Against
Janus Detroit Street Trust	0	257,889	0	Against
SEI	0	256,097	0	Against
Prudential/PGIM	0	243,921	0	Against
First Trust	0	236,665	0	Against
Columbia Threadneedle	0	236,483	0	Against
Jackson National	0	224,018	0	Against

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

11. Other Business

CORPORATE GOVERNANCE

0% fund support · no official result

AGAINST 100%

The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 92,917 against).

AGAINST: 92,917 (100.0%)

Largest asset managers voting on “Other Business” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	Against	Vote
Empower	85,034	Against
CLEARWATER INVESTMENT TRUST	6,693	Against
HC CAPITAL TRUST	1,190	Against

12. Election of Directors (Majority Voting)

DIRECTOR ELECTIONS

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors (Majority Voting)” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
AMERICAN PENSION INVESTORS TRUST	17,300	0	0	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	970	0	0	0	For

13. Ratify Appointment of Independent Auditors

AUDIT-RELATEDMajority of the votes cast: yes

99% Majority: yes · of votes cast

FOR 99%

FOR: 99,942,142AGAINST: 1,211,668

The 2 asset managers below cast 100% of the shares they voted on this item FOR (18,270 for, 0 against).

FOR 100%

FOR: 18,270 (100.0%)

Largest asset managers voting on “Ratify Appointment of Independent Auditors” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
AMERICAN PENSION INVESTORS TRUST	17,300	0	0	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	970	0	0	0	For

14. Say on pay

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 82,734,939AGAINST: 6,484,020

The 2 asset managers below cast 100% of the shares they voted on this item FOR (498 for, 0 against).

FOR 100%

FOR: 498 (100.0%)

Largest asset managers voting on “Say on pay” at Catalyst Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	498	0	0	0	For
Ikarian Capital, LLC	0	0	0	0	--

Largest Catalyst Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked by the number of Catalyst Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 121,959,172 shares outstanding at the time of that meeting.

Top Catalyst Pharmaceuticals, Inc. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	14.39%
2	Vanguard	7.02%
3	State Street	6.66%
4	Fidelity	2.65%
5	GEODE CAPITAL MANAGEMENT, LLC	2.26%
6	DEERFIELD MANAGEMENT COMPANY, L.P.	2.13%
7	Charles Schwab	2.08%
8	Fundsmith LLP	1.76%
9	Invesco	1.55%
10	Dimensional	1.53%

Reported Catalyst Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Catalyst Pharmaceuticals, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	15.42%	13F
Vanguard Group	6.97%	13F
State Street	4.53%	13F
Goldman Sachs	2.57%	13F
Deerfield Mgmt, L.P.	2.57%	13G
Renaissance Technologies	2.42%	13F
Geode Capital	2.27%	13F
Morgan Stanley	1.96%	13F
Dimensional Fund Advisors	1.79%	13F
Northern Trust	1.22%	13F

Percentages above are of 121,959,172 shares outstanding, as reported by Catalyst Pharmaceuticals, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Catalyst Pharmaceuticals, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Catalyst Pharmaceuticals, Inc.'s shareholder meeting held 2025-05-20, in the 2024-2025 proxy season, 390 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,140 separate fund positions. Their filings are grouped here into 14 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the 2024 compensation of our named executive officers. — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Catalyst Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-23.

Catalyst Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page).